

**Parkinson's Disease Schedule of Activities (Years 6+)**

Visit Number	R12	V13	R13	V14	R14	V15	R15	V16	R16	V17	R17	V18	R18	V19	R19	Annual	Remote	<sup>H</sup> Event Driven Modified Visit		
Assessment	<sup>**</sup> Timepoint		66 mths	72 (Y6)	78 mths	84 (Y7)	90 mths	96 (Y8)	102 mths	108 (Y9)	114 mth	120 (Y10)	126 mths	132 (Y11)	138 mths	144 (Y12)	150 mths	156+ (Y13+)	162 mths+	--
<b>Consent Activities</b>																				
Documentation of Informed Consent	As Needed																			
Continuing Consent		X		X		X		X		X		X		X		X		X		
Consent to share contact information	As Needed																			
Research Proxy Designation	As Needed																			
Informed Consent Tracking Log	As Needed																			
<b>General Activities</b>																				
myPPMI Registration <sup>S</sup>	As Needed																			
Vital Signs + Height and Weight		X		X		X		X		X		X		X		X		X		
Visit Status	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Conclusion of Study Participation	As Needed																			
<b>Neurological/Motor Assessments</b>																				
Participant Motor Function Questionnaire		P		P		P		P		P		P		P		P		P		
Freezing and Falls		X		X		X		X		X		X		X		X		X		
Neurological Examination		I		I		I		I		I		I		I		I		I		
Initiation of Dopaminergic Therapy	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
MDS-UPDRS Part Ia		I		I		I		I		I		I		I		I		I		
MDS-UPDRS Part Ib and Part II	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P	P
MDS-UPDRS Part III Treatment Determination/Motor Exam/Hoehn & Yahr <sup>d,e</sup>		I		I		I		I		I		I		I		I		I		
MDS-UPDRS Part IV <sup>d</sup>		I		I		I		I		I		I		I		I		I		
Modified Schwab & England ADL		I		I		I		I		I		I		I		I		I		
Features of Parkinsonism		I		I		I		I		I		I		I		I		I		
Other Clinical Features		I		I		I		I		I		I		I		I		I		
Primary Research Diagnosis		I		I		I		I		I		I		I		I		I		
Clinical Global Impression (CGI)		I		I		I		I		I		I		I		I		I		
Clinical Diagnosis	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
<b>Non-Motor Assessments</b>																				
REM Sleep Behavior Disorder Screening Questionnaire		P		P		P		P		P		P		P		P		P		
Epworth Sleepiness Scale		P		P		P		P		P		P		P		P		P		
SCOPA-AUT		P		P		P		P		P		P		P		P		P		
Participant Global Impression (PGI)		P		P		P		P		P		P		P		P		P		
PDAQ-27		P		P		P		P		P		P		P		P		P		
Neuro QoL		P		P		P		P		P		P		P		P		P		
<b>Cognitive Assessments</b>																				
Montreal Cognitive Assessment*		X		X <sup>M</sup>		X		X <sup>M</sup>		X		X <sup>M</sup>		X		X <sup>M</sup>		X		
Clock Drawing*				X				X				X				X				X <sup>L</sup>
Lexical Fluency*				X				X				X				X				X <sup>L</sup>
Hopkins Verbal Learning Test-Revised*				X				X				X				X				X <sup>L</sup>
Benton Judgment of Line Orientation*				X				X				X				X				X <sup>L</sup>
Modified Semantic Fluency (Animals only)*				X				X				X				X				X <sup>L</sup>
Letter Number Sequencing*				X				X				X				X				X <sup>L</sup>
Symbol Digit Modalities Test*				X				X				X				X				X <sup>L</sup>
Trail Making Test (A and B)*				X				X				X				X				X <sup>L</sup>
Modified Boston Naming Test*				X				X				X				X				X <sup>L</sup>

**Parkinson's Disease Schedule of Activities (Years 6+)**

Visit Number	R12	V13	R13	V14	R14	V15	R15	V16	R16	V17	R17	V18	R18	V19	R19	Annual	Remote	#Event Driven Modified Visit	
<b>Assessment</b>	<b>**Timepoint</b>	<b>66 mths</b>	<b>72 (Y6)</b>	<b>78 mths</b>	<b>84 (Y7)</b>	<b>90 mths</b>	<b>96 (Y8)</b>	<b>102 mths</b>	<b>108 (Y9)</b>	<b>114 mth</b>	<b>120 (Y10)</b>	<b>126 mths</b>	<b>132 (Y11)</b>	<b>138 mths</b>	<b>144 (Y12)</b>	<b>150 mths</b>	<b>156+ (Y13+)</b>	<b>162 mths+</b>	--
Cognitive Change		P		P		P		P		P		P		P		P			
Cognitive Categorization		I		I		I		I		I		I		I		I			
<b>Neuropsychological Assessments</b>																			
State-Trait Anxiety Inventory for Adults		P		P		P		P		P		P		P		P			
Geriatric Depression Scale		P		P		P		P		P		P		P		P			
QUIP		P		P		P		P		P		P		P		P			
<b>Clinical and Biological Samples</b>																			
Research Biosamples (blood + urine)		X		X		X		X		X		X		X		X			
Lumbar puncture				X				X				X						X <sup>L</sup>	
Skin biopsy																			
<b>Imaging Activities</b>																			
Pregnancy Test (prior to tracer injection), if applicable		X																	
Dopamine Imaging <sup>K</sup>		X																	
MRI <sup>K</sup>		X																	
<b>Safety and General Health</b>																			
# Adverse Events		X		X				X				X				X			
# Adverse Event Telephone Assessment		X		X				X				X				X			
Current Medical Conditions Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Concomitant Medication Review	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Participation in Other Studies		As Needed																	
LEDD Concomitant Medication Log		As Needed																	
Procedure for PD Log		As Needed																	
Report of Pregnancy		As Needed																	

I = Investigator (or trained designee) completed assessment

P = Participant completed assessment

X = Investigator or Coordinator completed assessment (or as otherwise delegated)

R0X Visits are conducted remotely (e.g., video, audio)

d = Investigator or Coordinator may complete treatment and timing information.

e = If the participant is on levodopa, dopamine agonists, or has had DBS, the MDS-UPDRS Part III should be performed in the ON state only.

H= see protocol section 11 for modification of visit schedule due to New Clinical Diagnosis, Need for PD Therapy or withdrawal from study

K = If participant is beyond Year 6, conduct this activity at next annual visit, as well as AE and AE telephone assessment

L= Cadence should continue to follow every 2 years.

M= If MoCA is 15 or less, full cognitive battery is optional (if tolerated).

S= Site to inform about myPPMI and assist with registration, if not yet done.

\*Completed on paper source first, and then scores entered in to EDC.

\*\*Window of +45 days either side of Target Visit Date

# Adverse events collected only day of and 2-3 business days post Dopamine Imaging, LP and skin biopsy per protocol.

As needed assessments can be located under the Event Driven category in EDC